Description:

Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Keywords:
Versions (1) ▾
  1. 4/21/21
Copyright Holder:
GlaxoSmithKline
Uploaded on:

April 21, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410)

Laboratory Tests - Haematology; Blood Chemistry; Urinalysis

Administrative
Laboratory Tests - Haematology
Visit
Day 1 not required
Haematology Test
Haematology Value
Are there clinically significant abnormal laboratory values?
Laboratory Tests - Blood Chemistry
Visit
Day 1 not required
Blood Chemistry Test
Blood Chemistry Value
Serum Beta HCG
Are there clinically significant abnormal laboratory values?
Laboratory Tests - Urinalysis
Visit
Urinalysis Test
Urinalysis Value
Was microscopy performed?
Microscopy
Microscopy Result
Are there clinically significant abnormal laboratory values?

Similar models